SLIT-ROBO Rho GTPase activating protein 1Genealiases: ARHGAP13 · NMTC2
Q-omics provides the consensus-scored SRGAP1 profile across patient tissues and cancer cell-line models. SRGAP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SRGAP1 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, SRGAP1 RNA expression shows 19,861 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRP as cancer lineages where SRGAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRGAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRGAP1 survival associations across molecular data types. SRGAP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRGAP1 RNA expression–survival associations across cancer types. High SRGAP1 expression shows unfavorable associations in UVM, MESO, LUAD, BLCA and KIRP, but favorable associations in SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SRGAP1 RNA expression.
This table summarizes SRGAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SRGAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRGAP1 shows higher tumor expression in KIRP, HNSC, BLCA, STAD, LIHC and CHOL. The KIRP box plot shows higher SRGAP1 RNA expression in tumor versus normal tissue (log2 FC = +1.078, t-test p < 0.001).
This table shows molecular features associated with SRGAP1 in patient tissues and cancer cell lines. In patient samples, SRGAP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRGAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
